Cardiovascular surgery (London, England) · 1996
Thrombolytic therapy for acute deep venous thrombosis: how much is enough?
СтатьяПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Comerota A J, Katz M L, White J V
Аннотация
Twenty-eight patients treated with thrombolytic therapy for acute deep venous thrombosis were monitored prospectively with non-invasive testing every 12-24h during treatment to evaluate thrombus response and whether duration of therapy was appropriate. Some 75% (21 of 28) of patients demonstrated improvement with lytic therapy with 36% (10 of 28) demonstrating complete lysis; 95% of responders (20 of 21) initiated lysis within 24h. Some 33% (7 of 21) of all responders and 64% (7 of 11) of those having partial lysis had treatment terminated during thrombus resolution but before maximal lysis. Non-invasive testing indicated that thrombolytic therapy for acute deep venous thrombosis is frequently terminated before maximal lysis of the thrombus. Monitoring thrombus response with venous duplex imaging should be part of the treatment strategy of deep venous thrombosis if thrombolytic therapy is used. This approach should increase efficacy and potentially reduce complications of thrombolytic therapy for acute deep venous thrombosis.
Предметные рубрики MeSH
Acute DiseaseFemoral VeinFibrin Fibrinogen Degradation ProductsFibrinogenFibrinolysisFibrinolytic AgentsHemorheologyHemorrhageHumansIliac VeinInjections, IntravenousMonitoring, PhysiologicPartial Thromboplastin TimePopliteal VeinProspective StudiesRemission InductionStreptokinaseThrombin TimeThrombolytic TherapyThrombophlebitisThrombosisTime FactorsUltrasonography, Doppler, DuplexUrokinase-Type Plasminogen Activator